Prestige BioPharma (950210.KS) Earnings Analysis
Prestige BioPharma (950210.KS) has no confirmed upcoming earnings date. Trailing P/E -5.49.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 950210.KS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 950210.KS. This page updates as the calendar is published.
950210.KS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-03-31 | 838.4 KRW | n/a | n/a | n/a |
| 2024-12-31 | -223.20138 KRW | n/a | n/a | n/a |
| 2024-09-30 | -96.2613 KRW | n/a | n/a | n/a |
950210.KS valuation and analyst view
| Trailing P/E | -5.49 |
|---|---|
| Trailing EPS | -957.50686 KRW |
| Price / book | 0.66 |
| Dividend yield | 0.00% |
| Market cap | 306.49B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Prestige BioPharma (950210.KS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 950210.KS. This page updates as the calendar is published.
Did 950210.KS beat earnings last quarter?
Consensus estimate data was not available for 950210.KS's 2025-03-31 report.
What is 950210.KS's current P/E ratio and EPS?
950210.KS trades at a trailing P/E of -5.49 on trailing EPS of -957.5068556975506 KRW.
What do analysts rate 950210.KS?
950210.KS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.